Showing posts with label Seattle Genetics. Show all posts
Showing posts with label Seattle Genetics. Show all posts
Monday, August 27, 2012
Genentech seeks approval of 'armed antibody' targeting breast cancer
Genentech Inc.’s one-two cancer-fighting punch – an antibody-drug conjugate called T-DM1 – extended the lives of women with a type of metastatic breast cancer compared to patients on another therapy, the South San Francisco-based company said Sunday. Genentech, the U.S. subsidiary of Swiss drug maker Roche, did not disclose a specific length of time by which T-DM1, or trastuzumab emtansine, extended the lives of HER2-positive metastatic breast cancer patients over a group of patients given a combination of the drugs Tykerb and Xeloda. Genentech said it has submitted a biologics license application, which is similar to a new drug application, for T-DM1 to the Food and Drug Administration. An FDA decision on the drug could come by mid-2013. The agency in 2010 refused to consider Genentech’s application for accelerated approval based on data from a Phase II study.
Subscribe to:
Posts (Atom)